The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanoma

The phase I study of the combined immunotherapy using alpha-galactosylceramide pulsed antigen presenting cells and tumor-specific peptide pulsed dendritic cells for patients with advanced head and neck mucosal melanoma - The phase I study with alpha-GalCer pulsed APCs and tumor peptide pulsed DCs for head and neck mucosal melanoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011508

Enrollment

Registered

2013-08-18

Start date

2013-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck mucosal malignant melanoma

Interventions

The injections of 100 millions of alpha-GalCer pulsed APCs and 0.5 millions of peptide pulsed DCs on day 7 into nasal submucosa. The injections of 100 millions of alpha-GalCer pulsed APCs and 1 milli

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced head and neck mucosal malignant melanoma; untreatable; HLA-A*2402 positive; pathological diagnosis of melanoma; ; Performance status is 0-2; Normal bone marrow and liver functions; written informed concent

Exclusion criteria

Exclusion criteria: Past histry of hepatitis; a positive response for HBs antigen/HCT antibody/HIV antibody/HTL-V1 antibody; recieived concurrent corticosteroid therapy; pregnancy or lactation; antoimmune disease; infection; uncontrolled diabetes mellitus; pulmonary fibrosis; serious cardiac disease; double cancer; large pleural effusions: brain metastasis judgement of physician

Design outcomes

Primary

Measure	Time frame
Safety profile	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026